TREPONEMA PALLIDUM IGM^

The TREPONEMA PALLIDUM IGM^ test detects IgM antibodies directed against Treponema pallidum, the bacterium that causes syphilis. Performed on a blood sample (serum or plasma) using immunoassay technology, it is designed to identify the early immune response soon after infection, often before IgG antibodies are detectable. Early identification of IgM can enable prompt clinical assessment and treatment, reducing the risk of progression and transmission.

This test is suitable for adults in Dubai who have had recent high‑risk exposure, present with symptoms such as a painless chancre, unexplained rash (including palms/soles), or swollen lymph nodes, or who require early screening following a partner’s positive result. Samples can be collected discreetly at home by trained phlebotomists and are processed in Dubai‑licensed laboratories; reactive or indeterminate IgM results typically require confirmatory testing with additional treponemal and non‑treponemal assays and follow‑up by a clinician.

• Treponema pallidum IgM Antibodies (Qualitative)
• Test Result: Reactive / Non‑reactive / Indeterminate
• Signal‑to‑Cutoff (Index) Value
• Sample Type: Serum or Plasma
• Collection Method: Venous blood (home phlebotomy)

• Within 2–6 weeks after suspected exposure to syphilis
• Presence of a painless genital, oral, or anal chancre
• Unexplained rash, particularly involving palms or soles
• Swollen lymph nodes or systemic symptoms after a high‑risk contact
• Screening after a sexual partner is diagnosed with syphilis

• Early detection of recent syphilis infection through IgM serology
• Discreet at‑home blood collection by trained phlebotomists
• Processing in Dubai‑licensed laboratories with confidential reporting
• Faster turnaround to support prompt clinical treatment and counselling
• Clear result interpretation with recommendation for confirmatory testing

• At‑home venous blood collection by a certified phlebotomist (or clinic draw)
• No fasting required; remain hydrated before sample collection
• Valid identification and signed consent required; generally for individuals aged 18+ under UAE lab regulations
• Notify the phlebotomist or clinician of recent antibiotic, immunoglobulin, or active treatment